Authors' Reply to Patel and Lucke-Wold

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Authors' Reply to Patel and Lucke-Wold Publisher

Mahmoodkhani M¹ ; Shafiei M¹ ; Sharifi M² ; Naeimi A³ ; Tehrani DS⁴

Show Affiliations

1. Department of Neurosurgery, School of Medicine, Neurosciences Research Center, Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2. Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3. School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
4. Department of Information Technology, Shahid Beheshti University, Tehran, Iran

Source: Cancer Research, Statistics, and Treatment Published:2023

[No abstract available]

Style	Citing Format
MLA	Mahmoodkhani M, et al.. "Authors' Reply to Patel and Lucke-Wold." Cancer Research, Statistics, and Treatment, vol. 6, no. 2, 2023, pp. 332-333.
APA	Mahmoodkhani M, Shafiei M, Sharifi M, Naeimi A, Tehrani DS (2023). Authors' Reply to Patel and Lucke-Wold. Cancer Research, Statistics, and Treatment, 6(2), 332-333.
Chicago	Mahmoodkhani M, Shafiei M, Sharifi M, Naeimi A, Tehrani DS. "Authors' Reply to Patel and Lucke-Wold." Cancer Research, Statistics, and Treatment 6, no. 2 (2023): 332-333.
Harvard	Mahmoodkhani M et al. (2023) 'Authors' Reply to Patel and Lucke-Wold', Cancer Research, Statistics, and Treatment, 6(2), pp. 332-333.
Vancouver	Mahmoodkhani M, Shafiei M, Sharifi M, Naeimi A, Tehrani DS. Authors' Reply to Patel and Lucke-Wold. Cancer Research, Statistics, and Treatment. 2023;6(2):332-333.
BibTex	@article{ author = {Mahmoodkhani M and Shafiei M and Sharifi M and Naeimi A and Tehrani DS}, title = {Authors' Reply to Patel and Lucke-Wold}, journal = {Cancer Research, Statistics, and Treatment}, volume = {6}, number = {2}, pages = {332-333}, year = {2023} }
RIS	TY - JOUR AU - Mahmoodkhani M AU - Shafiei M AU - Sharifi M AU - Naeimi A AU - Tehrani DS TI - Authors' Reply to Patel and Lucke-Wold JO - Cancer Research, Statistics, and Treatment VL - 6 IS - 2 SP - 332 EP - 333 PY - 2023 ER -